AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Investigational SERM increased lumbar spine BMD by 2%.(Gynecology)
SAN ANTONIO -- The next generation selective-estrogen receptor modulator lasofoxifene increased vertebral bone mineral density better than did raloxifene, according to the findings of a company-sponsored trial presented at the annual meeting of the American College of Rheumatology.
In the study, 410 postmenopausal women were randomly assigned to one of two doses of lasofoxifene, 0.25 mg or 1 mg daily; raloxifene at 60 mg daily, or a placebo.
The half-life of lasofoxifene is about a week versus 28 hours for raloxifene, according to Andy Lee, a director with Pfizer Global Research and Development, New London, Conn.
A new drug application for lasofoxifene has been submitted to the Food and Drug Administration for approval.
Lasofoxifene increased bone mineral density (BMD) at the lumbar spine by a mean of about 2% after 2 years of treatment. That compared with no mean improvement in spine BMD--but no density loss--in the patients assigned to raloxifene, and a 2% decrease in density in patients assigned to placebo.
BMD at the total hip improved by a mean of 1% for patients taking either raloxifene or lasofoxifene; total hip BMD remained the same in patients taking ...
- Pfizer Submits SNDA to Expand Potential Market for Lasofoxifene; Triggers...
- Press release article from: Business Wire February 3, 2005 700+ words
...this additional indication, lasofoxifene could provide an important...Portman et al. shows that lasofoxifene but not raloxifene (Evista(R)) significantly...improvements in vaginal atrophy by lasofoxifene compared to placebo." Under...
- Benefits outweigh lasofoxifene's risks in select women.(Metabolic Disorders)
- Magazine article from: Family Practice News Mechcatie, Elizabeth November 1, 2008 700+ words
...benefits of treatment with lasofoxifene, a selective estrogen...common among those on lasofoxifene were cancer (cancers...approved, Pfizer will market lasofoxifene under the trade name Fablyn. Raloxifene, another FDA-approved...
- Ligand Earns Milestone as Pfizer Submits NDA for Lasofoxifene for Osteoporosis;...
- Press release article from: Business Wire September 17, 2004 700+ words
...Phase II studies show that lasofoxifene has an improved profile...current leading SERM, raloxifene (Evista(R)). Similarly...also more pronounced with lasofoxifene than with the standard dose of raloxifene. Phase III data submitted...
- Lasofoxifene cut breast ca by 81% in phase III trials: fractures decreased 24%...
- Magazine article from: OB GYN News Jancin, Bruce January 15, 2009 700+ words
...Risk Reduction With Lasofoxifene) trial, Andrea Z...trials of tamoxifen and raloxifene, the two approved...women randomized to lasofoxifene at 0.5 mg/day...an amazing finding. Lasofoxifene was actually more effective...either tamoxifen or raloxifene in reducing the risk...
- Pfizer Receives FDA Complete Response Letter for Lasofoxifene.
- Press release article from: Business Wire January 16, 2009 700+ words
...for the European Union. About Lasofoxifene Lasofoxifene is a selective estrogen receptor...in the same chemical class as raloxifene. With its high affinity for estrogen receptors, lasofoxifene acts as an agonist in bone and...
- Long-term lasofoxifene preserves bone health in menopause models.
- Newspaper article from: Health & Medicine Week May 10, 2004 700+ words
...amp; NewsRx.net) -- Long-term lasofoxifene preserves bone health in menopause...determine the long-term effects of lasofoxifene, a new selective estrogen receptor...age were OVX and treated orally with lasofoxifene (60, 150, or 300 mcg/kg.d...
- Pfizer to Focus On Lasofoxifene -- CP336,156 -- for Osteoporosis and Breast...
- Press release article from: Business Wire December 23, 1999 700+ words
...to proceed to Phase III trials for lasofoxifene, currently in Phase II trials, and...milestones for the continued development of lasofoxifene as well as a royalty equal to 6% of...s choice to continue development of lasofoxifene is encouraging for women who suffer...
- Ligand Earns Milestone from Pfizer as Lasofoxifene Enters Phase III for...
- Press release article from: Business Wire September 26, 2000 700+ words
...initiation of Phase III clinical trials of lasofoxifene, a selective estrogen receptor modulator...reported data from Pfizer has shown that lasofoxifene in Phase II clinical studies increased...Preclinical study results reported for lasofoxifene also show prospects for this agent...
Source: HighBeam Research, Investigational SERM increased lumbar spine BMD by 2%.(Gynecology)